ECSP17072984A - Procesos farmacéuticos novedosos - Google Patents

Procesos farmacéuticos novedosos

Info

Publication number
ECSP17072984A
ECSP17072984A ECIEPI201772984A ECPI201772984A ECSP17072984A EC SP17072984 A ECSP17072984 A EC SP17072984A EC IEPI201772984 A ECIEPI201772984 A EC IEPI201772984A EC PI201772984 A ECPI201772984 A EC PI201772984A EC SP17072984 A ECSP17072984 A EC SP17072984A
Authority
EC
Ecuador
Prior art keywords
novel pharmaceutical
cab
pharmaceutical processes
vonoprazan
revaprazan
Prior art date
Application number
ECIEPI201772984A
Other languages
English (en)
Inventor
Richard Jenkins
Mark Hibberd
Original Assignee
Takeda Pharmaceuticals Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55806738&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP17072984(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1505526.2A external-priority patent/GB201505526D0/en
Priority claimed from GBGB1521015.6A external-priority patent/GB201521015D0/en
Application filed by Takeda Pharmaceuticals Co filed Critical Takeda Pharmaceuticals Co
Publication of ECSP17072984A publication Critical patent/ECSP17072984A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La invención proporciona un bloqueador de ácido competitivo con potasio (P-CAB) para usarse en el tratamiento, prevención y/o reducción de síntomas de la enfermedad por reflujo gastroesofágico (ERGE) en pacientes que responden de manera parcial a un inhibidor de la bomba de protones (IBP). El P-CAB puede, por ejemplo, seleccionarse de 1-[5- (2-fluorofenil)- 1-(piridin- 3-ilsulfonil)- 1H-pirrol- 3-il]- N-metilmetanamina (vonoprazan), revaprazan (YH1855), YH4808, RQ-4 y CS-526, o una sal de los mismos.
ECIEPI201772984A 2015-03-31 2017-10-31 Procesos farmacéuticos novedosos ECSP17072984A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1505526.2A GB201505526D0 (en) 2015-03-31 2015-03-31 Novel pharmaceutical uses
GBGB1521015.6A GB201521015D0 (en) 2015-11-27 2015-11-27 Novel pharmaceutical uses

Publications (1)

Publication Number Publication Date
ECSP17072984A true ECSP17072984A (es) 2018-02-28

Family

ID=55806738

Family Applications (1)

Application Number Title Priority Date Filing Date
ECIEPI201772984A ECSP17072984A (es) 2015-03-31 2017-10-31 Procesos farmacéuticos novedosos

Country Status (22)

Country Link
US (2) US20180085361A1 (es)
EP (1) EP3277279A1 (es)
JP (1) JP2018513140A (es)
KR (1) KR20170132260A (es)
CN (1) CN107530335A (es)
AU (1) AU2016241069A1 (es)
BR (1) BR112017021024A2 (es)
CA (1) CA2981244A1 (es)
CL (1) CL2017002325A1 (es)
CO (1) CO2017010019A2 (es)
CR (1) CR20170404A (es)
DO (1) DOP2017000218A (es)
EA (1) EA201792148A1 (es)
EC (1) ECSP17072984A (es)
IL (1) IL254419A0 (es)
MA (1) MA41850A (es)
MX (1) MX2017012414A (es)
PE (1) PE20180195A1 (es)
PH (1) PH12017501751A1 (es)
SG (1) SG11201706739WA (es)
TN (1) TN2017000416A1 (es)
WO (1) WO2016159386A1 (es)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11696893B2 (en) 2017-07-10 2023-07-11 Takeda Pharmaceutical Company Limited Preparation comprising vonoprazan

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2980109A1 (en) 2015-03-31 2016-10-06 Mutabilis Heterocyclic compounds and their use in preventing or treating bacterial infections
WO2024027549A1 (zh) * 2022-08-04 2024-02-08 江苏柯菲平医药股份有限公司 一种含有吡咯类胃酸分泌抑制剂的药物组合物及其制备方法
CN116270443A (zh) * 2022-10-27 2023-06-23 广州白云山天心制药股份有限公司 富马酸伏诺拉生注射液及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7662832B2 (en) 2004-09-03 2010-02-16 Yuhan Corporation Pyrrolo[2,3-c]pyridine derivatives and processes for the preparation thereof
US20080255200A1 (en) * 2007-04-11 2008-10-16 Auspex Pharmaceuticals, Inc. Substituted benzimidazoles
BRPI0916689A2 (pt) 2008-07-28 2015-11-17 Takeda Pharmaceutical composição farmacêutica estabilizada, preparação sólida, e, métodos para estabilizar uma composição farmacêutica, e para estabilizar uma preparação sólida.
WO2011004882A1 (ja) 2009-07-09 2011-01-13 ラクオリア創薬株式会社 消化管運動異常が関与する疾患を治療するためのアシッドポンプ拮抗剤
CA2902624C (en) 2013-02-28 2021-05-18 Takeda Pharmaceutical Company Limited Method for producing sulfonyl chloride compound
CN103951652B (zh) * 2014-04-18 2015-09-23 潍坊博创国际生物医药研究院 5-(2-氟苯基)-n-甲基-1-(3-吡啶基磺酰基)-1h-吡咯-3-甲胺水溶性有机酸盐和注射剂及它们的制备方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11696893B2 (en) 2017-07-10 2023-07-11 Takeda Pharmaceutical Company Limited Preparation comprising vonoprazan

Also Published As

Publication number Publication date
CA2981244A1 (en) 2016-10-06
PH12017501751A1 (en) 2018-04-11
CR20170404A (es) 2018-01-10
CN107530335A (zh) 2018-01-02
TN2017000416A1 (en) 2019-01-16
EP3277279A1 (en) 2018-02-07
MX2017012414A (es) 2018-01-26
PE20180195A1 (es) 2018-01-26
WO2016159386A1 (en) 2016-10-06
CO2017010019A2 (es) 2018-02-20
US20180085361A1 (en) 2018-03-29
US20190070159A1 (en) 2019-03-07
BR112017021024A2 (pt) 2018-07-03
DOP2017000218A (es) 2018-01-31
MA41850A (fr) 2018-02-06
SG11201706739WA (en) 2017-09-28
CL2017002325A1 (es) 2017-12-29
IL254419A0 (en) 2017-11-30
EA201792148A1 (ru) 2018-02-28
AU2016241069A1 (en) 2017-09-21
JP2018513140A (ja) 2018-05-24
KR20170132260A (ko) 2017-12-01

Similar Documents

Publication Publication Date Title
ECSP17072984A (es) Procesos farmacéuticos novedosos
CY1123833T1 (el) Μεθοδοι προληψης καρδιαγγειακων συμβαντων σε δυσλιπιδαιμικους πληθυσμους υπολειπομενου κινδυνου
MA40893A (fr) Dérivés de phényltriazole à substitution hydroxyalkyle et utilisations associées
AR090269A1 (es) Composicion farmaceutica y sus usos
BR112015020466A2 (pt) inibidores de cdc7
EA201892202A1 (ru) Способы лечения холестатических заболеваний
UY32424A (es) Comprimidos conteniendo elivitegravir para tratamiento de infecciones virales
MX2018003832A (es) Inhibidor de piridina alquinil prolil hidroxilasa, y metodo de preparacion y uso medico del mismo.
CL2011000806A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion del ictus en pacientes que padecen fibrilacion auricular.
CO2017008115A2 (es) Ácido (2s,4r)-5-(5'-cloro-2'-fluorobifenil-4-il)-4-(etoxioxalilamino)-2-hidroximetil-2-metilpentanoico
CY1123728T1 (el) (2r,4r)-5-(5'-χλωρο-2'-φθοροδιφαινυλ-4-υλ) -2-υδροξυ-4- [(5-μεθυλοξαζολο-2-καρβονυλ) αμινο] πεντανοϊκο οξυ
EA201892475A1 (ru) Оксабороловые сложные эфиры, их применение
WO2015112902A3 (en) CYSTATHIONINE-(gamma)-LYASE (CSE) INHIBITORS FOR TREATING PAIN
CY1124397T1 (el) Κρυσταλλικο (2s,4r)-5-(5'-χλωρο-2-φθορο-[1,1'-διφαινυλ] -4-υλ)-2-(αιθοξυμεθυλ)-4-(3-υδροξυϊσοξαζολη-5- καρβοξαμιδο) -2-μεθυλπεντανοϊκο οξυ και χρησεις αυτου
MX2018008614A (es) Inhibidores de il-8 para usarse en el tratamiento de neuropatia periferica inducida por quimioterapia.
EA201691498A1 (ru) Новая мишень для лечения и профилактики диабета
CL2011000805A1 (es) Uso de etexilato de dabigatran o una sal del mismo para preparar un medicamento util para la prevencion de lictus en pacientes que padecen fibrilacion auricular.
CO2018002046A2 (es) Nueva composición oral de libreación retardada dual de dexlansoprazol
CO2017011264A2 (es) El compuesto 1-(2-aminoetil)-6-(2-(2-hidroxietoxi)-5-metilfenil)-2-tioxo-2,3-dihidropirimidin-4(1h)-ona, sales, composiciones que lo comprenden y procedimientos de elaboración del mismo
FR3056908B1 (fr) Sel de metformine et d'elafibranor presentant une activite duale pour le traitement de l'obesite associee a la steato-hepatite non alcoolique (nash) et a l'hypertriglyceridemie
AR103219A1 (es) Compuesto de (1h-indol-3-il)propan-1-ona, composición farmacéutica, combinación y mezcla que lo comprenden y su uso para la fabricación de un medicamento
MX2017004359A (es) Composiciones farmaceuticas que comprenden alpelisib.
WO2020136298A3 (es) Inhibidores de la caspasa 1 para uso en el tratamiento de la anemia
MD1094Y (ro) Metodă de diagnostic al bolii de reflux gastroesofagian
CO2019005207A2 (es) Complejo medicinal para tratar diabetes tipo 2 y dislipidemia diabética